MedTrace Logo

PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations

NCT02983058 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-06-02

Study results available
· View outcomes & findings →

Summary

The primary goal of the present study is to evaluate the utility of mGluR5 binding as measured by PET as biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.

Conditions

Interventions

RADIATION

PET/SPECT Scan

PET scan will be performed on a mCT scanner

DEVICE

MRI Scan

Structural MRI will be obtained to permit co-registration of PET images

Sponsors & Collaborators

  • Jeffrey A. Lieberman, MD

    lead OTHER

Principal Investigators

  • Sander Markx, MD · New York State Psychiatric Institute

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-07-31
Completion
2017-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02983058 on ClinicalTrials.gov